reports
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infec...
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today its strategic focus on dedicating its resources to advancing the clinical development of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties. The Com...
Revive Therapeutics Provides Update on Research Study Evaluating Bucil...
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with ...
Revive Therapeutics Provides Update on Research Study Evaluating Bucil...
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Resear...
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical...
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the Type C meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) for the evaluation of a propo...
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Di...
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product TORONTO, June 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) of the Revive LC POC Lateral Flow Test Kit (the “Product”) fo...
Revive Therapeutics Announces Type C Meeting Request Granted by FDA fo...
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company’s Type C meeting request for the evaluation of a proposed clinical s...
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Lo...
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s meeting request for the Revive LC POC Lateral Flow Test Kit (the “Product”) for feedback...
Revive Therapeutics Provides Update on Psilocybin Clinical Study for M...
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s clinical study (the “Study”) () evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an investigator-i...
Revive Therapeutics Submits Type C Meeting Request Package to FDA for ...
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has submitted a Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug ...
Revive Therapeutics To Submit Type C Meeting Request with FDA for Buci...
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties,...
Revive Therapeutics Provides Corporate Update
Revive Therapeutics Provides Corporate Update TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product. Bucillamine The Company is advancing the research and development of Bucillamine, an oral thiol-based drug with anti-inflammatory and a...
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tra...
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it has completed the second and final tranche of its previously announced private placement (see January 24, 2024 and January 31, 2024 press releases) (the “Offering”) ...
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
Revive Therapeutics Explores the Use of Bucillamine for Long COVID TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company aims to advance the clinical development of Bucillamine by leveraging the published res...
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its...
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500 NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it has completed the first tranche of its previously announced private placement (see January 24, 2024 press release) (the “Offering”) by issuing 26,100,000 units (each, a “Unit”)...
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it is arranging a private placement of a maximum of 85,714,285 units (each, a “Unit”), at a price of $0.035 per Unit, for gross proceeds of up to $3 million (the “Offering”). Each Unit shall be comprised of one common share (“Common Sha...
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve A...
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of ...
Revive Therapeutics Successfully Completes Development of a Novel Lyop...
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has completed the formulation development work of the Company’s next-generation lyophilized formulation of Bucillamine (“New Bucillamine”) conducted at the University of Waterloo. The New Buci...
Revive Therapeutics Announces Results of Annual General and Special Me...
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders TORONTO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the results of its annual general and special meeting of shareholders held Tuesday, December 19, 2023 (the “Meeting”) in Toronto, Ontario. All matters presented to the shareholders of the Company (the “Shareholder...
Revive Therapeutics Collaborates with Attwill Medical Solutions for th...
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine TORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has signed a collaboration agreement with Attwill Medical Solutions LP (“AMS”) for the clinical and commercial development of the Company’s...
Revive Therapeutics Provides Update of Novel Bucillamine Formulation D...
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development TORONTO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine. Under an agreement with the University of Waterloo, formulation development work is ongoing and is expected to be completed by the end of the year....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.